bispecific T-cell engaging antibodies (Abzyme Therapeutics)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug Namebispecific T-cell engaging antibodies (Abzyme Therapeutics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsLyme Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAbzyme Therapeutics Llc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbzyme Therapeutics Llc

Active IndicationsN/A

Inactive IndicationsLyme Disease

Other Information

ATC CodeN/A